Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

Science Translational Medicine

Volumn 8, Issue 370, 2016, Pages

  Mathios, Dimitrios ^a   Kim, Jennifer E ^a   Mangraviti, Antonella ^a   Phallen, Jillian ^a   Park, Chul Kee ^a,b   Jackson, Christopher M ^a   Garzon Muvdi, Tomas ^a   Kim, Eileen ^a   Theodros, Debebe ^a   Polanczyk, Magdalena ^a   Martin, Allison M ^a   Suk, Ian ^a   Ye, Xiaobu ^a   Tyler, Betty ^a   Bettegowda, Chetan ^a   Brem, Henry ^a   Pardoll, Drew M ^a   Lim, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; PROGRAMMED CELL DEATH PROTEIN 1 ANTIBODY; PROTEIN ANTIBODY; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENDRITIC CELL; DRUG MEGADOSE; EFFECTOR CELL; FEMALE; GLIOBLASTOMA; IMMUNE RESPONSE; LEUKOCYTE; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; BRAIN TUMOR; C57BL MOUSE; DISEASE EXACERBATION; DISEASE MODEL; FLOW CYTOMETRY; GLIOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICROGLIA; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85006987606     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag2942     Document Type: Article

References (21)

1. R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. B. Taphoorn, R. C. Janzer, S. K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A. A. Brandes, J. Gijtenbeek, C. Marosi, C. J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R.-O. Mirimanoff; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
2. W. H. Brooks, M. G. Netsky, D. E. Normansell, D. A. Horwitz, Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136, 1631-1647 (1972).
3. S. A. Grossman, X. Ye, G. Lesser, A. Sloan, H. Carraway, S. Desideri, S. Piantadosi; NABTT CNS Consortium, Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin. Cancer Res. 17, 5473-5480 (2011).
4. G. Lombardi, E. Rumiato, R. Bertorelle, D. Saggioro, P. Farina, A. Della Puppa, F. Zustovich, F. Berti, V. Sacchetto, R. Marcato, A. Amadori, V. Zagonel, Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: A prospective study. Am. J. Clin. Oncol. 38, 514-519 (2013).
5. J. R. Brahmer, H. Hammers, E. J. Lipson, Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol. 11, 1307-1326 (2015).
6. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
7. D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
8. R. G. van der Most, B. W. Robinson, R. A. Lake, Combining immunotherapy with chemotherapy to treat cancer. Discov. Med. 5, 265-270 (2005).
9. C. Jackson, J. Ruzevick, H. Brem, M. Lim, Vaccine strategies for glioblastoma: Progress and future directions. Immunotherapy 5, 155-167 (2013).
10. A. B. Fleming, W. M. Saltzman, Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. 41, 403-419 (2002).
11. A. J. Litterman, A. Z. Dudek, D. A. Largaespada, Alkylating chemotherapy may exert a uniquely deleterious effect upon neoantigen-targeting anticancer vaccination. Oncoimmunology 2, e26294 (2013).
12. D. T. Le, E. M. Jaffee, Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Res. 72, 3439-3444 (2012).
13. Y. Hailemichael, W. W. Overwijk, Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int. J. Biochem. Cell Biol. 53, 46-50 (2014).
14. O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, L. E. French, Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176, 61-67 (2006).
15. A. J. Litterman, D. M. Zellmer, K. L. Grinnen, M. A. Hunt, A. Z. Dudek, A. M. Salazar, J. R. Ohlfest, Profound impairment of adaptive immune responses by alkylating chemotherapy. J. Immunol. 190, 6259-6268 (2013).
16. J. Zeng, A. P. See, J. Phallen, C. M. Jackson, Z. Belcaid, J. Ruzevick, N. Durham, C. Meyer, T. J. Harris, E. Albesiano, G. Pradilla, E. Ford, J. Wong, H.-J. Hammers, D. Mathios, B. Tyler, H. Brem, P. T. Tran, D. Pardoll, C. G. Drake, M. Lim, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343-349 (2013).
17. F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, K. Tamada, L. Chen, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096 (2005).
18. J. R. Ohlfest, B. M. Andersen, A. J. Litterman, J. Xia, C. A. Pennell, L. E. Swier, A. M. Salazar, M. R. Olin, Vaccine injection site matters: Qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J. Immunol. 190, 613-620 (2013).
19. T. Reithmeier, E. Graf, T. Piroth, M. Trippel, M. O. Pinsker, G. Nikkhah, BCNU for recurrent glioblastoma multiforme: Efficacy, toxicity and prognostic factors. BMC Cancer 10, 30 (2010).
20. R. J. Tamargo, J. S. Myseros, J. I. Epstein, M. B. Yang, M. Chasin, H. Brem, Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res. 53, 329-333 (1993).
21. M. L. Affronti, C. R. Heery, J. E. Herndon II, J. N. Rich, D. A. Reardon, A. Desjardins, J. J. Vredenburgh, A. H. Friedman, D. D. Bigner, H. S. Friedman, Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115, 3501-3511 (2009).